GlassScriptPhysician profile
Jacob Nicholas Hall
NPI 1194068031
$20,044.54
in general payments reported to CMS, 2019-2025
50 companies · $3,126 in 2025
The $3,126 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $380 · 2021: $5,863 · 2022: $2,177 · 2023: $4,066 · 2024: $4,432 · 2025: $3,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,519.41 |
| Education | $105.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $5,406.96 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Abbvie INC. | $3,771.37 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,171.75 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $999.89 | 2023-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $955.17 | 2021-2025 | |
| Ucb, INC. | $911.49 | 2022-2025 | Briviact, Zilbrysq, Fintepla |
| Lilly USA, LLC | $762.84 | 2020-2025 | Amyvid, Kisunla, Reyvow |
| Emd Serono, INC. | $624.05 | 2022-2025 | Mavenclad, Mavenclad |
| Pfizer INC. | $565.10 | 2023-2025 | |
| Neurelis, INC. | $476.41 | 2020-2025 | Valtoco |
| Eisai INC. | $392.72 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $384.27 | 2022-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $310.84 | 2023-2025 | Crexont, Rytary |
| Lundbeck LLC | $309.50 | 2020-2025 | Vyepti, Rexulti |
| Sunovion Pharmaceuticals INC. | $303.67 | 2021-2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $255.36 | 2022 | |
| Allergan, INC. | $208.29 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $204.26 | 2023-2025 | Spravato |
| Tg Therapeutics, INC. | $147.29 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $146.36 | 2022-2023 | Trudhesa |
| Sk Life Science, INC. | $124.18 | 2020-2024 | |
| Grifols USA, LLC | $122.72 | 2023-2025 | Gamunex-C, Xembify |
| E.R. Squibb & Sons, L.L.C. | $117.25 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $114.71 | 2022-2025 | Xeomin, Inbrija |
| Amgen INC. | $106.95 | 2021-2024 | Uplizna, Aimovig |
| Mdd US Operations, LLC | $104.14 | 2025 | Qelbree, Gocovri |
| Csl Behring | $91.88 | 2022-2024 | Hizentra |
| Biohaven Pharmaceuticals, INC. | $89.80 | 2020-2021 | |
| Catalyst Pharmaceuticals, INC. | $71.74 | 2024-2025 | |
| Horizon Therapeutics Plc | $68.18 | 2022-2023 | Uplizna |
| Janssen Biotech, INC. | $57.58 | 2025 | |
| Genentech USA, INC. | $55.41 | 2023-2024 | Ocrevus |
| Octapharma USA, INC. | $53.21 | 2023-2024 | Panzyga |
| Celgene Corporation | $52.75 | 2020-2024 | Zeposia |
| Corium, LLC | $50.68 | 2022-2023 | Adlarity |
| Upsher-Smith Laboratories LLC | $50.39 | 2021 | |
| Genzyme Corporation | $47.30 | 2022-2023 | |
| Grt US Holding, INC. | $46.54 | 2022 | |
| Tanabe Pharma America, INC. | $40.33 | 2024 | |
| Microtransponder, INC. | $39.08 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $31.86 | 2023 | Dysport |
| Amicus Therapeutics, INC. | $29.35 | 2023 | |
| Impel Pharmaceuticals LLC | $24.94 | 2024 | Trudhesa |
| Averitas Pharma INC. | $24.70 | 2024 | Qutenza |
| Insightec,INC | $24.59 | 2024 | Exablate |
| Kyowa Kirin, INC. | $21.66 | 2024 | Nourianz |
| Aquestive Therapeutics, INC. | $20.76 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.38 | 2024 | Hyqvia |
| Philips North America LLC | $18.84 | 2024 | (5091) Amb Mon & Diag Und |
| Cycle Pharmaceuticals INC | $15.05 | 2025 | Tascenso Odt, Bafiertam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.